Nymox Pharmaceutical Corp (NYMXF)

[mlkrborn]

12:31PM Nymox Pharma reports that recruitment will begin for NX02-0020, a small open-label short-term safety study of NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (NYMX) 7.15 +0.19 : The study will enroll approximately 100-200 subjects who have already participated in previous studies of NX-1207. The study will assess the safety of repeat injection of the drug. Previous studies of NX-1207 have been single injection only. Eligible subjects will be enrolled from approximately 70 U.S. clinical trial sites. The study will run concurrently with the large pivotal Phase 3 studies of NX-1207 which are ongoing. NX02-0020 is expected to be concluded before the pivotal studies NX02-0017 and NX02-0018 are completed. For each enrolled subject in the new trial, participation will last 90 days.